1RV Aperçu des actions Rhythm Pharmaceuticals, Inc. est une société biopharmaceutique en phase de commercialisation qui se concentre sur les maladies neuroendocriniennes rares. Plus de détails
Récompenses Analyse des risques Voir tous les contrôles de risques Saisissez vos pensées, vos liens et l'histoire de votre entreprise
Rhythm Pharmaceuticals, Inc. Concurrents Historique des prix et performances
Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Rhythm Pharmaceuticals Historique des cours de bourse Prix actuel de l'action US$57.50 Plus haut sur 52 semaines US$62.50 Plus bas sur 52 semaines US$32.20 Bêta 2.17 Variation sur 1 mois 4.55% Variation sur 3 mois 27.78% Variation sur 1 an 52.12% Variation sur 3 ans 592.77% Variation sur 5 ans 193.37% Évolution depuis l'introduction en bourse 165.14%
Nouvelles et mises à jour récentes
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05 Voir plus de mises à jour
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (Setmelanotide) for Patients as Young as 2 Years Old Dec 21
Rhythm Pharmaceuticals Announces IMCIVREE (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old Dec 03
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, Including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide Nov 19
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in the Lancet Diabetes & Endocrinology Nov 14
Third quarter 2024 earnings released: US$0.73 loss per share (vs US$0.76 loss in 3Q 2023) Nov 07
Rhythm Pharmaceuticals Announces Five New Data Presentations At Obesityweek 2024 Nov 05
Rhythm Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 05, 2024 Oct 23
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for Imcivree® (Setmelanotide) in Patients as Young as 2 Years Old Aug 26
Second quarter 2024 earnings released: US$0.55 loss per share (vs US$0.82 loss in 2Q 2023) Aug 07
Forecast to breakeven in 2026 Aug 07
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old Jul 31 Rhythm Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024
Rhythm Pharmaceuticals, Inc. Announces Appointment of Alastair Garfield, as Chief Scientific Officer Jul 08
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index Jul 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome Jun 29
New minor risk - Profitability May 09
No longer forecast to breakeven May 08
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 08
First quarter 2024 earnings released: US$2.35 loss per share (vs US$0.92 loss in 1Q 2023) May 07
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology Apr 30
Rhythm Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024 Apr 28
Rhythm Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 26
New major risk - Financial position Apr 04
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 03 Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management Apr 02
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist Mar 27 Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals Mar 21
Full year 2023 earnings released: US$3.20 loss per share (vs US$3.48 loss in FY 2022) Feb 23
Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan Feb 23
New minor risk - Profitability Feb 09
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Feb 07
Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 01
New major risk - Share price stability Jan 23
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: US$0.76 loss per share (vs US$0.80 loss in 3Q 2022) Nov 09
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide) Nov 03
Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome Sep 07
Second quarter 2023 earnings released: US$0.82 loss per share (vs US$0.89 loss in 2Q 2022) Aug 02
Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 18
Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023 Jun 19
Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients May 09
First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022) May 03
Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021) Mar 02
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome Jan 24
Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome Nov 22
Third quarter 2022 earnings released: US$0.80 loss per share (vs US$0.70 loss in 3Q 2021) Nov 09
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology Nov 09
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023 Nov 03
Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA Nov 02
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development Oct 07
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022 Sep 20
Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide) Sep 07
Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021) Aug 03
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome Jul 23
Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France Jul 21
NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency Jul 19
Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity Jul 13
Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment Jun 23
Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome Jun 17
Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022 Jun 14
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting May 04
Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity Apr 07
Forecast to breakeven in 2024 Feb 26
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome Feb 25 Rhythm Pharmaceuticals, Inc. Announces Executive Promotions
Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS) Feb 17 Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder
High number of new directors Nov 04
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain Sep 23
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes Sep 21
Chief Medical Officer Murray Stewart has left the company Sep 15
Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome Sep 10
Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity Aug 05
Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE Jul 25 Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index
Independent Director Todd Foley has left the company Jun 15
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency May 22
Chief Human Resources Officer has left the company May 01
Chairman recently bought €172k worth of stock Apr 01
Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss At Up to Nine Months in Patients with Het Obesity on Setmelanotide At Endo 2021 Mar 21
Rhythm Pharmaceuticals, Inc. Announces Board Changes Mar 17
New 90-day low: €20.80 Mar 06
Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities Jan 29
New 90-day high: €31.20 Jan 23
New 90-day high: €26.80 Jan 07
Rhythm Pharmaceuticals, Inc. Announces Committee Appointments Jan 05 Rendement pour les actionnaires 1RV DE Biotechs DE Marché 7D 6.5% 2.5% -0.4% 1Y 52.1% -10.2% 7.9%
Voir le rapport complet des actionnaires
Rendement vs Industrie: 1RV a dépassé le secteur German Biotechs qui a rapporté -10.2 % au cours de l'année écoulée.
Rendement vs marché: 1RV a dépassé le marché German qui a rapporté 7.9 % au cours de l'année écoulée.
Volatilité des prix Is 1RV's price volatile compared to industry and market? 1RV volatility 1RV Average Weekly Movement 8.0% Biotechs Industry Average Movement 7.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Cours de l'action stable: Le cours de l'action de 1RV a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de 1RV ( 8% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de German.
À propos de l'entreprise Rhythm Pharmaceuticals, Inc. est une société biopharmaceutique en phase de commercialisation qui se concentre sur les maladies neuroendocriniennes rares. Le principal produit candidat de la société est IMCIVREE (setmelanotide), un récepteur rare de la mélanocortine 4 pour le traitement de l'obésité par déficit en pro-opiomélanocortine (POMC), en proprotéine convertase subtilisine/kexine de type 1, en récepteur de la leptine (LEPR), et du syndrome de Bardet-Biedl et d'Alström. Il fait l'objet d'essais cliniques de phase 3 pour le traitement de l'obésité par déficit hétérozygote en POMC ou LEPR, de l'obésité par déficit en coactivateur du récepteur des stéroïdes 1, de l'obésité par déficit en SH2B1, de l'obésité par déficit en récepteur MC4 et d'autres troubles liés au MC4R.
Afficher plus Rhythm Pharmaceuticals, Inc. Résumé des fondamentaux Comment les bénéfices et les revenus de Rhythm Pharmaceuticals se comparent-ils à sa capitalisation boursière ? 1RV statistiques fondamentales Capitalisation boursière €3.56b Bénéfices(TTM) -€253.83m Recettes(TTM ) €109.20m
Bénéfices et recettes Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM) 1RV compte de résultat (TTM ) Recettes US$112.53m Coût des recettes US$12.81m Marge brute US$99.72m Autres dépenses US$361.29m Les revenus -US$261.57m
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
Résultat par action (EPS) -4.26 Marge brute 88.61% Marge bénéficiaire nette -232.45% Ratio dettes/capitaux propres 71.5%
Quelles ont été les performances à long terme de 1RV?
Voir les performances historiques et les comparaisons
Analyse de l'entreprise et données financières Données Dernière mise à jour (heure UTC) Analyse de l'entreprise 2025/01/05 15:14 Cours de l'action en fin de journée 2025/01/03 00:00 Les revenus 2024/09/30 Revenus annuels 2023/12/31
Sources de données Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC . Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
Paquet Données Cadre temporel Exemple de source américaine * Finances de l'entreprise 10 ans Compte de résultat Tableau des flux de trésorerie Bilan Estimations consensuelles des analystes +3 ans Prévisions financières Objectifs de prix des analystes Prix du marché 30 ans Cours des actions Dividendes, scissions et actions Propriété 10 ans Actionnaires principaux Délits d'initiés Gestion 10 ans L'équipe dirigeante Conseil d'administration Principaux développements 10 ans
* exemple pour les titres américains, pour les titres non-américains des formulaires et sources réglementaires équivalents sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). Pour en savoir plus , cliquez ici .
Modèle d'analyse et flocon de neige Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github . Nous avons également des guides sur la façon d'utiliser nos rapports et des tutoriels sur Youtube .
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur .
Sources des analystes Rhythm Pharmaceuticals, Inc. est couverte par 18 analystes. 12 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
Analyste Institution Tazeen Ahmad BofA Global Research Whitney Ijem Canaccord Genuity Corinne Johnson Goldman Sachs
Afficher 15 plus d'analystes 
